Founded in 2007, Genor Biopharma Co. Ltd. (Genor BioPharma, Stock code: 6998.HK) is an innovation-driven biopharma company with a pipeline of therapies covering the world's most prevalent cancer types (breast, lung, and gastrointestinal cancer) and hematological malignancies.
Genor Biopharma strives to build an innovative, platform-oriented and integrated company with innovative drug R&D, preclinical research, clinical development, regulatory, and CMC development.
Successfully set up an early discovery platform with first in class (FIC)/differentiated T-cell Engager (T-cell Engager) bi-specific/multi-specific antibodies in immune-oncology / bispecific antibody-drug conjugates (BsADC). The focus is to conduct molecular research that have the potential to become global best-in-class (BIC) products and have the greatest potential to produce clinical and commercially viable drugs.
The industry-leading R&D center has extensive large molecule CMC (Chemistry, Manufacturing, and Controls) development experience. It is capable of developing comprehensive bioprocesses and formulations, and manufacturing preclinical and clinical materials with advanced analytical, quality control, and quality assurance systems for compliance.
Beijing office
Yuxi, Yunnan - Principally Phase 3 and commercial manufacturing
Zhangjiang, Shanghai - R&D center, QC/Analytical center, cGMP sample manufacturing
South San Francisco, US - Bi-specific platform
We aspire to become a biopharmaceutical company with global presence, serving patients and society.
Our mission is to become a biopharmaceutical engine in discovery, research, development, manufacturing and commercialization of innovative therapeutics initially for patients in China and gradually for patients globally.
Our History
December 2007
Genor Biopharma was incorporated in Shanghai as one of the first innovation-driven biopharmaceutical company.
July 2014
Yuxi Genor was incorporated in Yuxi, Yunnan, PRC
April 2016
Manufactory facility was constructed in Yuxi, Yunan
April 2017
Genor Biopharma was incorporated in Cayman Islands.
December 2018
Completed Series A Financing
September 2019
Differentiated Antibody Discovery Platform, Ab Therapeutics, was established in SF, USA
May 2020
Completed Series B Financing
October 2020
Genor was successfully listed on HKEX (stock code 6998.HK) and raised USD$400mn
December 2021
A number of world-renowned experts in tumor immunology & clinical oncology have been appointed as members of the Biosciences Advisory Board
February 2022
GB242 (Infliximab, biosimilar to Remicade, Jiayoujian佳佑健®) received NDA approval in the treatment of Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriasis, Adult Ulcerative Colitis, Adult and Pediatric Crohn’s Disease and Fistulising Crohn’s Disease.
June 2022
The company entered into a cooperative development agreement with Abogen to jointly develop globally innovative mRNA products and related pharmaceuticals.
2022 January to December
achieved a number of important milestones at a speed better than the industry average
View More
2023 March
NMPA has officially accepted the new drug application for GB491 (Lerociclib) in combination with Fluvestran as the treatment of HR+/HER2- locally advanced or metastatic breast cancer patients with disease progression following previous endocrine therapy.